MDWD

MediWound Ltd.

Healthcare
Biotechnology
$168M market cap

Forecast run · Sep 14, 2026Upside rank 1533 of 3,136

Model Signal

ForecastQ Daily Probabilities

34.4%

34.1%

9.8%

Analyst Consensus

Recommendation2.00/5 Buy

Last price$13.11

Price target$26.00

Implied move+98.3%

Analysts13

ForecastQ Portfolios

MDWD is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.